Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI.

Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c.

PMID:
19434004
2.

Novel dual Src/Abl inhibitors for hematologic and solid malignancies.

Schenone S, Brullo C, Musumeci F, Botta M.

Expert Opin Investig Drugs. 2010 Aug;19(8):931-45. doi: 10.1517/13543784.2010.499898. Review.

PMID:
20557276
3.

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, OcaƱa A, Pandiella A.

Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Review.

4.

[SRC kinases in tumor therapy].

Dempke W, Zippel R.

Med Klin (Munich). 2010 Oct;105(10):711-5. doi: 10.1007/s00063-010-1123-y. Epub 2010 Oct 28. Review. German.

PMID:
20981590
5.

An update on dual Src/Abl inhibitors.

Musumeci F, Schenone S, Brullo C, Botta M.

Future Med Chem. 2012 Apr;4(6):799-822. doi: 10.4155/fmc.12.29. Review.

PMID:
22530642
6.

Current status of SRC inhibitors in solid tumor malignancies.

Puls LN, Eadens M, Messersmith W.

Oncologist. 2011;16(5):566-78. doi: 10.1634/theoncologist.2010-0408. Epub 2011 Apr 26. Review.

7.

Dasatinib: an anti-tumour agent via Src inhibition.

Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.

Curr Drug Targets. 2011 Apr;12(4):563-78. Review.

PMID:
21226671
8.

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Araujo J, Logothetis C.

Cancer Treat Rev. 2010 Oct;36(6):492-500. doi: 10.1016/j.ctrv.2010.02.015. Epub 2010 Mar 11. Review.

9.

Bosutinib for the treatment of chronic myeloid leukemia.

Doan V, Wang A, Prescott H.

Am J Health Syst Pharm. 2015 Mar 15;72(6):439-47. doi: 10.2146/ajhp140221. Review.

PMID:
25736937
10.

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.

Keller G, Schafhausen P, Brummendorf TH.

Expert Rev Hematol. 2009 Oct;2(5):489-97. doi: 10.1586/ehm.09.42. Review.

PMID:
21083014
11.

Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

Syed YY, McCormack PL, Plosker GL.

BioDrugs. 2014 Feb;28(1):107-20. doi: 10.1007/s40259-013-0082-x. Review.

PMID:
24420842
12.

Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Ahluwalia MS, de Groot J, Liu WM, Gladson CL.

Cancer Lett. 2010 Dec 8;298(2):139-49. doi: 10.1016/j.canlet.2010.08.014. Review.

13.

The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.

Lieu C, Kopetz S.

Clin Colorectal Cancer. 2010 Apr;9(2):89-94. doi: 10.3816/CCC.2010.n.012. Review.

14.

SRC: a century of science brought to the clinic.

Aleshin A, Finn RS.

Neoplasia. 2010 Aug;12(8):599-607. Review.

Supplemental Content

Support Center